Ensysce Biosciences Inc.
Ensysce, a clinical-stage company, is using its proprietary TAAP and MPAR™ platforms to develop safer prescription drugs. Its lead drug candidate, PF614, will create a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdose. Our mission is to provide safer options to treat severe pain, reducing the human and economic costs caused by drug abuse
Phone (including country code)
The choice you make above will help our platform display content that is best suited to you
Welcome to the new Wholesale Investor platform. Please use your existing log in details to access the site. Alternatively feel free to use the "Login with LinkedIn" or "Sign in with Google" buttons.
Enter your email to reset your password.